CSL BEHRING LLC for CSL BEHRING LLC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2022 | $350,000 | Replaced |
| 2nd Quarter - Amendment | Oct 20, 2022 | $390,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 3808--Medicare IVIG Enhancement Act--Coverage for Intravenous immune globulin and its administration in the home under Medicare Part B when used for chronic inflammatory demyelinating polyneuropathy. HR 7346--Plasma Donation Awareness Act--Adding "and plasma" to the Blood Donation Awareness Campaign created by the CARES Act. Highlighting the importance and need of plasma collection as the raw material to manufacture therapies in treating rare diseases. HR 5376--Build Back Better Act/Budget Reconciliation--Medicare Part D restructure, direct negotiation of Medicare pricing, Medicare inflation caps, restriction on use of orphan drug tax credit. Highlighting issues that could arise if these measures are included in the Senate version of BBBA. HR 7389--MVP Act--Codify the CMS Medicaid Value Based Payment rule allowing for multiple best prices, modify the Average Manufacturers Price to accommodate value based arrangements, update anti-kickback regulations to ensure value based arrangements are compliant. S.4348/HR 7667--FDA Safety and Landmark Advancements Act/The FDA Food and Drug Amendments of 2022--Reauthorization of PDUFA (Prescription Drug User Fee Act) VII specific to FDA user fees. Advocating for language that would not hinder the accelerated approval pathway.
Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK COLLINS | — |
Immigration IMM
Customs and Border protection policy change on allowing B1/B2 visa holders to cross the US border to donate plasma.
Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK COLLINS | — |
| MARY LACEY REUTHER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.